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46 AT A GLANCE COMMENTARY 
 
47 Scientific knowledge on the subject 
 
48 Neutrophil elastase (NE) is a key risk factor for the onset and progression of structural lung 
 
49 disease in patients with cystic fibrosis (CF). Recent studies identified increased NE activity 
 
50 on the surface of neutrophils from airways of mice with CF-like lung disease and patients 
 
51 with CF, even in the absence of free NE activity in airway samples. However, the relationship 
 
52 between increased NE activity on the surface of airway neutrophils and severity of lung 
 
53 disease in patients with CF remains unknown. 
 
54 
 
55 What this study adds to the field 
 
56 This  study  investigated  the  relationship  between  NE  activity  on  the  surface  of  sputum 
 
57 neutrophils and severity of lung disease in adult patients with CF. We demonstrate that NE 
 
58 activity is increased on the surface of CF sputum neutrophils, even at low levels of free NE 
 
59 activity in cell-free sputum supernatants. Further, cell surface-bound NE activity correlated 
 
60 inversely with FEV1 % predicted and FRCpleth % predicted as outcome measures of airflow 
 
61 limitation  and  air  trapping.  These  results  suggest  that  surface-bound  NE  activity  may 
 
62 contribute to severity of lung disease and serve as a novel biomarker in patients with CF. 
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65 This article has an online data supplement, which is accessible from this issue’s table of 
 
66 content online at www.atsjournals.org. 
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69 ABSTRACT 
 
70 Rationale: Neutrophil elastase (NE) is a key risk factor for the onset and progression of 
 
71 cystic fibrosis (CF) lung disease. Recent studies identified increased NE activity on the 
 
72 surface of neutrophils from airways of mice with CF-like lung disease and patients with CF. 
 
73 However, the role of NE activity on neutrophil surfaces in CF lung disease remains unknown. 
 
74 Objectives: To determine the relationship between surface-bound NE activity on sputum 
 
75 neutrophils and severity of lung disease in patients with CF. 
 
76 Methods:  Surface-bound  NE  activity  was  measured  on  sputum  neutrophils  from  a 
 
77 prospective  cohort  of  35  patients  with  CF  using  novel  lipidated  and  soluble  Foerster 
 
78 resonance energy transfer (FRET) reporters and correlated with free NE activity, neutrophil 
 
79 counts, IL-8, MPO and antiproteases in cell-free sputum supernatants and with parameters 
 
80 of lung function. 
 
81 Measurement and main results Surface-bound NE activity on sputum neutrophils was 
 
82 increased in CF compared to heathly controls (P<0.01) and correlated with free NE activity 
 
83 (P<0.05), but not with other inflammation markers in CF sputum Surface-bound and free NE 
 
84 activity correlated with FEV1  % predicted (P<0.01 and P<0.05), but only surface-bound NE 
 
85 activity correlated with FRCpleth % predicted (P<0.01). 
 
86 Conclusions: Surface-bound NE activity on airway neutrophils is increased and correlates 
 
87 with severity of lung disease independent of other markers of inflammation in patients with 
 
88 CF. Surface-bound NE activity, probably reflecting a freshly secreted pool of NE not inhibited 
 
89 by  antiproteases,  may  play  an  important  role  in  the  pathogenesis  and  serve  as  novel 
 
90 biomarker of neutrophil activation in CF lung disease. 
 
 
91 
 
92 Abstract word count: 250 words 
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96 INTRODUCTION 
 
97 Chronic neutrophilic airway inflammation is a hallmark of cystic fibrosis (CF) and increased 
 
98 activity of neutrophil elastase (NE), a major product of activated neutrophils, has been 
 
99 identified as a key risk factor for the onset and progression of bronchiectasis and lung 
 
100 function decline in patients with CF (1–3). Beyond structural damage of airway walls, NE has 
 
101 been implicated in the pathogenesis of mucus hypersecretion (4–6), airway inflammation (7– 
 
102 9), and impaired defenses against Pseudomonas aeruginosa infection (10–14). In addition, 
 
103 
 
104 
increased  NE  activity  was  shown  to  disable  CF  transmembrane  conductance  regulator 
(CFTR) Cl-  channels and activate epithelial Na+  channels (ENaC), thus aggravating basic 
105 defects in anion secretion and Na+  absorption in CF airways (15–17). These results from 
 
106 observational and experimental studies suggest NE activity in airway specimen such as 
 
107 sputum  or  bronchoalveolar  lavage  (BAL)  fluid  as  a  promising  biomarker  of  neutrophilic 
 
108 inflammation in CF lung disease (2, 3). So far, measurements have focused on the detection 
 
109 of free NE activity in BAL and sputum supernatant (2, 3, 18–22). Since NE is a highly cationic 
 
110 molecule, a significant proportion of secreted NE is bound to the neutrophil membrane via 
 
111 electrostatic interactions (23–25). Using a novel Foerster resonance energy transfer (FRET)- 
 
112 based NE reporter assay (26), we recently demonstrated that NE activity is also increased on 
 
113 the surface of airway neutrophils in patients with CF (4). In addition, we showed that elevated 
 
114 surface-bound NE activity is implicated in airway inflammation, mucus hyper-secretion and 
 
115 structural lung damage in mice with CF-like lung disease, even in the context of moderate 
 
116 airway neutrophilia, where free NE is effectively inhibited by an intact antiprotease shield and 
 
117 no free  NE  activity  is  detectable  in  BAL  fluid  (4).  However,  the  role  of  NE  activity  on 
 
118 
 
119 
neutrophil surfaces in CF lung disease remains unknown. 
 
120 The aim of this study was, therefore, to determine the relationship between surface-bound 
 
121 NE activity on the cell membrane of airway neutrophils and the severity of lung disease in 
 
122 patients with CF. To achieve this goal, we collected sputum from a prospective cohort of 35 
 
123 patients with CF and 8 healthy non-smokers and used FRET reporters to quantify surface- 
3  
124 bound NE activity on sputum neutrophils and free NE activitiy in sputum supernatants. 
 
125 Further,  we  determined  sputum  neutrophil  counts  and  levels  of  interleukin-8  (IL-8), 
 
126 myeloperoxidase (MPO) and antiproteases such as α1-antitrypsin-NE complexes (AAT-NE) 
 
127 and secretory leukocyte protease inhibitor (SLPI) in sputum supernatant, performed paired 
 
128 pulmonary function testing, and correlated surface-bound NE activity with these markers of 
 
129 disease severity in patients with CF. Some of the results have been previously reported in 
 
130 
 
131 
 
132 
the form of abstracts (27, 28). 
 
133 METHODS 
 
134 Study population 
 
135 This  study  was  approved  by  the  ethics  committee  of  the  University  of  Heidelberg  and 
 
136 informed written consent was obtained from all subjects. The diagnosis of CF was verified by 
 
137 established  diagnostic  criteria  (29,  30).  Spontaneously  expectorated  (n=36)  or  induced 
 
138 sputum  (n=3)  of  sufficient  quantity  (total  cell  count  of  inflammatory  cells  >60,000)  was 
 
139 collected from 35 clinically stable patients with CF during routine visits at the CF Center at 
 
140 the University Hospital Heidelberg. Patient characteristics are summarized in Table 1 and 
 
141 CFTR genotypes are provided in Table E1. Colonization with Pseudomonas aeruginosa was 
 
142 defined as negative when 0%, intermittent when ≤50% and chronic when >50% of airway 
 
143 cultures were positive in the previous twelve month. Airflow obstruction and pulmonary 
 
144 hyperinflation were detected by measurement of forced expiratory volume in one second 
 
145 (FEV1) and plethysmographic functional residual capacity (FRCpleth) on the same day of 
 
146 sputum collection according to ATS/ERS guidelines (31, 32). As control group, we collected 
 
147 induced sputum from 8 age-matched, healthy, non-smoking volunteers (5 females and 3 
 
148 males;  median  age  31.1  range  22.01-45.02  years)  by  hypertonic  saline  inhalation  as 
 
149 previously described (4, 33). Briefly, the mouth was rinsed with water and 100 µg salbutamol 
 
150 was inhaled prior to 6% hypertonic saline. Sputum samples were directly collected in a 
 
151 specimen container, stored on ice immediately after production and processed within two 
4  
152 
 
153 
hours. 
 
154 Sputum  processing  and  measurements  of  free  and  surface-bound  NE  activity, 
 
155 cytokines and antiproteases 
 
156 Sputum was separated from saliva and homogenized using 10% sputolysin (Calbiochem, 
 
157 Darmstadt, Germany). Sputum inflammatory cells were isolated and total immune cell counts 
 
158 were performed. Free NE activity was quantified in sputum supernatants using the FRET 
 
159 probe NEmo-1 and compared with activity levels determined by the chromogenic substrate 
 
160 MeO-Suc-AAPV-pNA  (Sigma,  St  Louis,  MO,  USA)  (1–3).  Surface-bound  NE  activity  on 
 
161 sputum neutrophils was measured using the lipidated FRET reporter NEmo-2 (4, 26) and 
 
162 determined  from  the  ratio  of  donor  to  acceptor  fluorescence  (D/A  ratio)  as  previously 
 
163 described and detailed in the online supplement (4). Levels of IL-8, MPO, SLPI and AAT-NE 
 
164 were measured using ELISA. Differential cell counts were performed on May-Grünwald- 
 
165 Giemsa stained cytospin preparations. For three CF and one control subject, differential cell 
 
166 count could not be determined because the cytospins were of poor quality. Values below the 
 
167 
 
168 
detection limit are reported as 0. Additional information is provided in the online supplement. 
 
169 Statistical analysis 
 
170 Data were analyzed with “R” (R Foundation for Statistical Computing, Vienna, Austria) or 
 
171 
 
172 
SigmaPlot  (Systat  Software  GmbH,  Erkrath,  Germany)  and  are  reported  as  median 
(interquartile range, 25–75th percentile). Statistical analysis was performed using Shapiro-wilk 
173 test,  unpaired  Student’s  t  test,  Wilcoxon  rank  sum  test,  one-way  analysis  of  variance, 
 
174 Kruskal-Wallis test, Dunn’s test or Dunn’s test versus control as appropriate. Correlation 
 
175 analyses were performed using the Spearman rank order method. A P value less than 0.05 
 
176 was considered statistically significant. In the case of multiple comparisons, individual P 
 
177 
 
178 
 
179 
levels are indicated only if not rejected by the Bonferroni–Holm method. 
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180 RESULTS 
 
181 NE activity is increased on the surface of sputum neutrophils in CF, even in patients 
 
182 with low levels of free NE activity in sputum supernatant 
 
183 To determine surface-bound NE activity on airway neutrophils and its relationship with free 
 
184 NE activity in CF airway inflammation, we assessed prospectively collected sputum samples 
 
185 from 35 clinically stable adult patients with CF (Table 1) and 8 healthy non-smokers using 
 
186 highly  sensitive  NE-specific  FRET  reporters  developed  to  quantify  free  (NEmo-1)  and 
 
187 surface-bound  (NEmo-2)  NE  activity  (4,  26).  As  expected,  absolute  neutrophil  counts 
 
188 (P<0.001) and percentage of neutrophils (P<0.001) in sputum were significantly increased in 
 
189 our cohort of adult patients with CF compared to healthy controls (Figures 1A and 1B). Free 
 
190 NE activity detected by NEmo-1 was significantly increased in CF compared to control 
 
191 sputum (P<0.01), was completely inhibited by the NE inhibitor sivelestat (Figure 1D), and 
 
192 showed a strong correlation with free NE activity detected by the established chromogenic 
 
193 substrate MeO-Suc-AAPV-pNA (r=0.91, P<0.001 and Figure E1). Similar to free NE activity, 
 
194 surface-bound NE activity was significantly increased on CF compared to control neutrophils 
 
195 (P<0.01) and completely inhibited by sivelestat (Figure 1C and 1E). Surface-bound and free 
 
196 NE activity showed a moderate correlation in CF samples (P<0.05, Figure 1F). Of note, 
 
197 grouping of CF samples according to the levels (quartiles) of free NE activity in sputum 
 
198 
 
199 
supernatant demonstrated that surface-bound NE activity was significantly increased on CF 
compared to control neutrophils, even in patients with low levels (≤25th percentile) of free NE 
200 activity (P<0.01; Figure 1G). Taken together, these results demonstrate that, in addition to 
 
201 free NE activity in airway secretions, surface-bound NE activity on airway neutrophils is 
 
202 
 
203 
increased and contributes to the protease burden in the lungs of patients with CF. 
 
204 Relationship  of  surface-bound  and  free  NE  activity  with  markers  of  neutrophilic 
 
205 inflammation and antiproteases 
 
206 Next, we determined the relationship of free and surface-bound NE activity in CF sputum 
 
207 with markers of neutrophilic inflammation including neutrophil counts, IL-8 and MPO, and 
6  
208 antiproteases that inhibit NE activity in the airway lumen. Free NE activity in CF sputum 
 
209 supernatants correlated with absolute neutrophil counts, IL-8 and MPO (Figures 2A, C and 
 
210 E).  Surface-bound  NE  activity  did  not  correlate  with  these  markers  of  neutrophilic 
 
211 inflammation (Figures 2 B, D and F). Neither free nor surface-bound NE activity correlated 
 
212 with percentage of sputum neutrophils (r=0.11, P=0.53 and r=0.15, P=0.36). To investigate 
 
213 the relationship of free and surface-bound NE activity with antiproteases, we measured 
 
214 levels of SLPI and complexes of NE with α1-antitrypsin (AAT-NE), two major endogenous 
 
215 inhibitors of NE in the airways (34), in sputum supernatants. As expected from previous 
 
216 studies  (10,  35),  AAT-NE  was  significantly  increased  (P<0.001),  whereas  SLPI  was 
 
217 decreased (P<0.001) in CF compared to control sputum (Table 2). Free, but not surface- 
 
218 bound NE activity correlated with AAT-NE (Figure 2G and H). Neither free, nor surface- 
 
219 bound NE activity were correlated with SLPI (Figure 2I and J). Collectively, these data 
 
220 indicate that free NE activity depends on the level of airway inflammation, as determined 
 
221 from the number of neutrophils, levels of IL-8 and AAT-NE in sputum, whereas surface- 
 
222 bound NE activity is increased on CF neutrophils independent of these indices of neutrophilic 
 
223 
 
224 
airway inflammation. 
 
225 Surface-bound NE activity on sputum neutrophils correlates with airflow obstruction 
 
226 and air trapping 
 
227 To determine the clinical relevance of increased NE activity on the surface of CF neutrophils, 
 
228 we correlated free and surface-bound NE activity with FEV1 and (FRCpleth) as lung function 
 
229 parameters of airflow obstruction and air trapping. As expected from previous studies (3, 19, 
 
230 22, 36), free NE activity in CF sputum showed a negative correlation with FEV1 % predicted 
 
231 (P<0.05) in our cohort of patients with CF (Figure 3A), whereas no relationship was found 
 
232 between free NE and FRCpleth % predicted (Figure 3C). Surface-bound NE activity on CF 
 
233 sputum neutrophils was also inversely correlated with FEV1 % predicted (P<0.01, Figure 3B). 
 
234 In  addition,  surface-bound  NE  activity  was  directly  correlated  with  FRC  %  predicted  in 
 
235 patients with CF (P<0.01, Figure 3D). These results show that the level of surface-bound NE 
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236 activity is related to the severity of airflow obstruction and air trapping in adult patients with 
 
237 
 
238 
 
239 
CF. 
 
240 DISCUSSION 
 
241 The mucostatic environment in CF lung disease sustains a destructive cascade of oxidative 
 
242 stress, ineffective host defense and chronic infection, resulting in a massive recruitment of 
 
243 neutrophils to the lungs (37). During homing to the CF airways, viable neutrophils undergo 
 
244 activation and extensively mobilize NE-rich granula to the cell surface (38, 39). In vitro 
 
245 studies demonstrated that activated blood neutrophils express 6-fold more NE on the cell 
 
246 surface  than  is  freely  released,  whereas  unstimulaed  neutrophils  express  only  minimal 
 
247 amounts of NE on the cell surface (24). NE binds charge-dependently to low affinity, high 
 
248 volume binding sites on the neutrophil membrane (25) and surface-bound NE has a similar 
 
249 spectrum of catalytic activity and efficiency as free NE (24, 25, 40). The clinical relevance of 
 
250 NE activity on the cell surface of intact airway neutrophils in CF lung disease, however, 
 
251 remains unknown. Thus, we conducted this prospective, cross-sectional study in 35 patients 
 
252 with CF covering a wide spectrum of disease severity to compare the role of surface-bound 
 
253 with free NE activity in advanced CF lung disease. Our work shows for the first time that 
 
254 
 
255 
surface-bound NE activity is associated with severity of CF lung disease. 
 
256 Preclinical studies utilizing βENaC-overexpressing mice, an established model of CF-like 
 
257 lung disease, provided first insights into the pathophysiologic role of surface-bound NE 
 
258 activity in the context of early-onset airway mucus plugging, spontaneous bacterial infection 
 
259 and chronic airway inflammation (4, 41–44). Similar to mild lung disease in infants and young 
 
260 children with CF, this mouse model exhibits a moderate airway neutrophila with 5-30 % 
 
261 neutrophils in BAL fluid (1, 41, 44). Genetic deletion of NE demonstrated that a lack of NE 
 
262 significantly reduces airway inflammation, mucus hypersecretion and structural lung damage 
 
263 in βENaC-overexpressing mice. However, no free NE activity was detectable in the cell-free 
8  
264 supernatants of BAL fluid from βENaC-overexpressing mice, whereas surface-bound NE 
 
265 activity  on  BAL  neutrophils  was  constantly  increased.  This  was  likely  due  to  an  intact 
 
266 antiprotease shield, as BAL supernatants could inhibit activity of purified NE in a dose- 
 
267 dependent manner (4). So far, the massive influx, necrosis, cell lysis and impaired clearance 
 
268 of  neutrophils  has  been  considered  as  the  main  mechanism  leading  to  NE  burden  in 
 
269 advanced CF lung disease (37). In our cohort, sputum neutrophil counts were markedly 
 
270 elevated, consistent with reported neutrophil numbers in sputum from adult patients with CF 
 
271 (4,  20).  However,  we  found  that  surface-bound  NE  activity  was  increased  on  sputum 
 
272 neutrophils, even when free NE activity was low. Further, free but not surface-bound NE 
 
273 activity correlated with markers of neutrophilic airway inflammation and absolute neutrophil 
 
274 counts. This supports the hypothesis that viable, non-apoptotic airway neutrophils contribute 
 
275 to CF lung disease (38, 39) and proposes that surface-bound NE activity rather depicts 
 
276 neutrophil activation at the single cell level than unspecific NE liberation from disintegrating 
 
277 
 
278 
cells. 
 
279 In  the  lungs,  α1-antitrypsin  and  SLPI  are  the  most  abundant  serine  antiproteases  that 
 
280 counterbalance the harmful effects of excessive NE activity (34). The acute phase protein 
 
281 α1-antitrypsin  is  primarily  produced  in  the  liver,  distributed  via  the  blood  stream  and 
 
282 inactivates NE by forming stable complexes (34). SLPI is secreted locally in the airways by 
 
283 various cell types, including neutrophils, macrophages and airway epithelial cells, and is 
 
284 cleaved and inactivated by free NE (10). Studies on human BAL neutrophils have shown that 
 
285 surface-bound  NE  on  non-adherent  neutrophils  can  be  fully  inhibited  by  α1-antitrypsin, 
 
286 leading to  a  permanent  clearance  of  NE  from  the  cell  surface  (45).  In  our  CF  cohort, 
 
287 however, the antiprotease shield was considerably impaired, as SLPI was decreased and did 
 
288 not correlate with NE activity. Interestingly, free but not surface-bound NE activity correlated 
 
289 with NE-α1-antitrypsin-compexes. Therefore, we speculate that the high levels of free NE 
 
290 consume a significant proportion of α1-antitrypsin in advanced CF lung disease. Surface- 
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291 bound  NE  activity  might  represent  a  pool  of  freshly  secreted  NE,  not  inhibited  by  the 
 
292 
 
293 
antiproteasis shield. 
 
294 Finally, we could show that NE activity on sputum neutrophils was associated with impaired 
 
295 lung function in adult patients with CF. Both, free and surface-bound NE activities correlated 
 
296 with  FEV1   %  predicted,  the  most  widely  accepted  pulmonary  function  test  for  disease 
 
297 progression in CF. Moreover, the novel FRET approach demonstrated that surface-bound, 
 
298 but  not  free  NE  activity,  correlates  with  air  trapping,  a  surrogate  measure  for  airflow 
 
299 obstruction and structural lung damage in CF lung disease. This is in line with preclinical data 
 
300 in βENaC-overexpressing mice that identified surface-bound NE activity as a potent trigger of 
 
301 emphysematous airspace enlargement in CF-like lung disease (4). Recent CT studies have 
 
302 further highlighted the important pathophysiologic role of early-onset emphysema in patients 
 
303 with CF (46, 47). Mechanistically, It has been proposed that adherence of neutrophils to the 
 
304 site of proteolysis might protect surface-bound NE activity against endogenous antiproteases 
 
305 and thus aggravate local tissue damage (45). Taken together, these data suggest that 
 
306 surface-bound NE activity is associated with severity of CF lung disease and might be a 
 
307 
 
308 
sensitive measure for tissue destruction in CF airways. 
 
309 NE inhibitors are proposed as a promising anti-inflammatory and tissue-protective therapy in 
 
310 CF lung disease (48–50). This study confirms that NE needs to be inhibited and monitored 
 
311 on the neutrophil membrane for optimal therapeutic efficiency (4). Recent clinical studies in 
 
312 3-month-old infants with CF have shown that free NE activity in BAL fluid is the major risk 
 
313 factor for bronchiectasis at 12 month, but free NE activity was below the detection limit in 
 
314 more than 70 % of the analyzed samples (1, 2). This is similar to findings in βENaC- 
 
315 overexpressing mice, showing that free NE activity cannot be measured in cell-free BAL 
 
316 supernatans from mice with CF-like lung disease in presence of an intact antiprotease shield 
 
317 (4). Hence, more sensitive methods for the measurement of NE activity in airway secretions 
 
318 are required. The current study showed that even in adults with CF, surface-bound NE 
10  
319 activity can be increased when free NE activity is low. Further, our data have shown that 
 
320 surface-bound  NE  activity  was  independent  from  established  markers  of  neutrophilic 
 
321 inflammation. This proposes that quantification of surface-bound NE activity could serve as a 
 
322 
 
323 
high-sensitivity approach for detection of neutrophilic inflammation in airway secretions. 
 
324 An important limitation of this study is the single-center, cross-sectional design. Therefore, 
 
325 future longitudinal clinical studies are required to estimate the predictive value of surface- 
 
326 
 
327 
bound NE activity in stable CF lung disease and in exacerbation. 
 
328 In summary, this study demonstrated for the first time that NE activity on sputum neutrophils 
 
329 is associated with severity of CF lung disease. Our data suggest that surface-bound NE 
 
330 activity might represent neutrophil activation rather than neutrophil number. Further, the 
 
331 antiprotease shield predominantly counteracts free NE activity while freshly secreted NE on 
 
332 the neutrophil surface might be protected from endogenous inhibitors. Correlations with lung 
 
333 function data revealed that surface-bound NE activity is associated with both airflow limitation 
 
334 and air trapping. Taken together, our results suggest that NE activity on airway neutrophils 
 
335 may play an important role in pathogenesis and could provide a valuable biomarker for 
 
336 monitoring of progression in CF lung disease. 
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FIGURE LEGENDS 
 
 
 
 
Figure 1. NE activity is increased on the surface of CF sputum neutrophils. (A-B) Absolute (A) 
and relative (B) number of neutrophils in control and CF sputum. (C) Representative ratio 
images calculated from donor and acceptor fluorescence of sputum neutrophils from a healthy 
non-smoker (control) and a patient with cystic fibrosis (CF). (D-E) Free NE activity in sputum 
supernatants (D) and cell surface-bound NE activity on sputum neutrophils (E) from controls 
and patients with CF in the absence and presence of the NE inhibitor sivelestat. (F) Correlation 
between surface-bound and free NE activity in CF sputum. (G) Surface-bound NE activity on 
neutrophils from controls (Con) and stratified according to quartile groups of free NE activity in 
sputum from patients with CF (25: ≤25th percentile, 50: >25th-50th percentile, 75: >50th-75th 
percentile and 100: >75th-100th percentile). Dots represent individual samples and lines 
represent  the  group  median.  *P<0.05,  **P<0.01  and  ***P<0.001  compared  with  control. 
†P<0.001 compared with CF without sivelestat 
 
 
 
 
Figure 2. Relationship of free and surface-bound NE activity with parameters of neutrophilic 
inflammation and antiproteases in CF sputum. (A-J) Correlations of free NE activity in sputum 
supernatant (A,C,E,G,I) and surface-bound NE activity on sputum neutrophils (B,D,F,H,J) with 
neutrophil counts (A and B), and levels of interleukin-8 (IL-8) (C and D), myeloperoxidase 
(MPO) (E and F), α1-antitypsin-NE complexes (AAT-NE) (G and H) and secretory leukocyte 
protease inhibitor (SLPI) (I and J) in CF sputum. Spearman correlation coefficient r and P 
values are provided for each correlation. 
 
 
 
Figure 3. Relationship of free and surface-bound NE activity with lung function parameters of 
airflow obstruction and air trapping in patients with CF. (A-D) Correlations of free NE activity in 
sputum supernatant and surface-bound NE activity on sputum neutrophils with forced expiratory 
volume in one second % predicted (FEV1  % pred.) (A and B) and plethysmographic functional 
19  
residual capacity % predicted (FRCpleth % pred.) (C and D). Spearman correlation coefficient r 
and P values are provided for each correlation. 
20  
TABLES 
 
 
 
Table 1. Clinical characteristics of patients with cystic fibrosis 
 
Number of subjects 
 
Number of visits 
n 
 
n 
35 
 
39 
Age (years) Median (IQR) 27.7 (23.8–30.8) 
Range 19.1 – 59.0 
Sex n, males/females 23/12 
2 Median (IQR) 19.79 (18.88–21.43) 
Range 16.35– 27.72 
FEV  % predicted Median (IQR) 53.30 (38.70–68.10) 
Range 18.00 – 114.80 
FRCpleth % predicted* Median (IQR) 140.40 (113.78–169.38) 
Range 89.60–212.40 
CFTR genotype  
 
n (Percentage) 
 
 
13/35 (37.14%) F508del/F508del 
F508del/other n (Percentage) 19/35 (54.29%) 
other/other n (Percentage) 3/35 (8.57%) 
Pseudomonas infection  
 
n (Percentage) 
 
 
13/39 (33.33%) negative 
intermittent n (Percentage) 3/39 (7.69%) 
chronic n (Percentage) 23/39 (58.97%) 
Pancreatic insufficiency n (Percentage) 30/35 (83.33%) 
 
 
Definition of abbreviations: BMI: Body mass index, FEV1 % predicted: forced expiratory volume 
in one second % predicted, FRCpleth % predicted: plethysmographic functional residual 
capacity % predicted, IQR: interquartile range 25–75th percentile*FRCpleth % predicted 
determined by body plethysmography was available in 28 of 39 visits. 
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Table 2.Myeloperoxidase, antiproteases and IL-8 in control and CF sputum 
 
 Control CF P-value 
MPO 
 
SLPI (ng/mL) 
AAT-NE (ng/mL) 
IL-8 (ng/mL) 
0.41 (0.32–0.55) 
 
1211.55 (923.27–1811.72) 
 
24.84 (15.62–33.24) 
 
0.56 (0.29–0.80) 
29.69 (18.44–51.81) 
 
180.81 (87.30–474.10) 
 
82.57 (40.41–183.14) 
 
11.15 (8.23–16.58) 
<0.001 
 
<0.001 
 
<0.001 
 
<0.001 
 
Definition of abbreviations: MPO: myeloperoxidase, SLPI: secretory leukocyte protease 
inhibitor, AAT-NE: α1-antitrypsin-NE complexes, IL-8: interleukin-8. 
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